Skip to content

Ronny Allan – Living with Neuroendocrine Cancer

  • Home Page
  • About
    • Join the Support Group
    • Recommendations
    • My Diagnosis and Treatment
      • My Neuroendocrine Cancer Surgery – Small Intestine NET, a patient experience (part 1)
      • My Neuroendocrine Cancer Surgery – a patient experience (part 2)
      • My liver rescetion
      • My lymphadenectomy
    • Ronny’s Video Presentations
    • Health Union Patient Leader
    • Disclaimer
    • Award Winning Blog
  • A spotlight on NENs
    • A spotlight on NENs – Types
      • A spotlight on Small Intestine Neuroendocrine Tumours
      • A spotlight on Appendiceal Neuroendocrine Neoplasms
      • A spotlight on duodenal Neuroendocrine Neoplasms (dNENs)
      • A spotlight on Rectal Neuroendocrine Neoplasms
      • A Spotlight on Lung Neuroendocrine Neoplasms
      • Neuroendocrine Tumours: a spotlight on Pheochromocytoma and Paraganglioma
      • A spotlight on Grade 3 (High grade) Neuroendocrine Neoplasms
    • A spotlight on NENs – Syndromes
      • A Spotlight on Neuroendocrine Cancer Syndromes – Carcinoid Syndrome
    • A Spotlight on NENs – Testing
      • Tumour markers and Hormone Levels
      • A spotlight on Chromogranin A
      • A spotlight on 5-HIAA
      • The NETest® – a Chromogranin A replacement and more?
  • Epidemiology
    • Neuroendocrine tumors are uncommon but definitely not rare
    • Neuroendocrine Neoplasms – not as rare as you think
    • The Invisible NET Patient Population 
    • Genetics
      • Neuroendocrine Neoplasms (NEN) – genetic related syndromes
      • A spotlight on Multiple Endocrine Neoplasia (MEN)
  • NET Guidelines
  • Diagnosis and Surveillance
    • Neuroendocrine Neoplasms – Classification, Grade and Stage
    • A spotlight on Gastric Neuroendocrine Neoplasms
    • Where to find a NET Specialist worldwide
    • 10 questions to ask your doctor
    • Diagnosing the Undiagnosed
    • A needle in a haystack?
    • Marker Tests
    • Syndromes and Symptoms
      • I bet my flush beats yours?
      • Neuroendocrine Cancer – the diarrhea jigsaw
      • The Syndromes of Neuroendocrine Cancer – Early Signs of a Late Diagnosis
      • Hormones
      • Neuroendocrine Cancer: Clinical Esoterica
      • Gallium 68 PET Scans – Into the Unknown
      • Serotonin – the NET effect
      • Cancer-related fatigue (CRF) – Neuroendocrine Cancer
      • Imaging
        • Neuroendocrine Cancer – If you can see it, you can detect it!
        • Ga68 PET Scan – a game changer?
        • Neuroendocrine Tumours – now you see them, now you don’t!
        • Detectnet™ (64Cu-DOTATATE) – an expansion of the Somatostatin Receptor PET Imaging for Neuroendocrine Cancer
        • Understanding your Somatostatin Receptor (SSTR) PET/CT Scan Results
  • Treatments
    • Treatment – a summary for patients
    • Surgery
      • Surgery for Neuroendocrine Neoplasms – to cut or not to cut?
      • Surgery for NETs – Chop Chop
      • Surgery is risky but so is driving a car
      • Small intestine, large surgery
      • Pancreatic Neuroendocrine Tumours – surgical decisions
      • Neuroendocrine Cancer – my liver surgery
    • Liver Embolization (bland, chemo, radio)
    • Somatostatin Receptors
    • PRRT
      • Peptide Receptor Radionuclide Therapy (PRRT)
      • Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future
    • Somatostatin Analogues
      • Somatostatin Analogues for Neuroendocrine Cancer: Lanreotide and Octreotide
      • Lanreotide – it’s calling the shots!
      • At home with Lanreotide (….and Octreotide)
      • Somatostatin Analogues and delivery methods in the pipeline
    • Everolimus (Afinitor)
    • Sunitinib (Sutent)
    • Chemotherapy
    • Telotristat Ethyl (XERMELO®)
  • Diet and Nutrition
    • Q. The best diet for Neuroendocrine Cancer? A. The one that works for you.
    • Article 1 – Vitamin and Mineral Challenges
    • Article 2 – Gastrointestinal Malabsorption
    • Article 3 – Gut Health
    • Article 4 – Food for Thought?
    • Article 5 – Pancreatic Enzyme Replacement Therapy (PERT)
    • Article 6 – featuring the 2020 video series by Tara Whyand RD
    • The trouble with the NET (Part 5) – Cancer Diet Myths
    • Lactose intolerance – the NET Effect
    • Fructose intolerance – the NET Effect
    • Low FODMAPs – The NET Effect
    • Low and High Residue Foods
  • Clinical Trials and Research
  • Awareness Posts
    • The Trouble with the NET Series
    • The NET Effect Series
    • All Awareness Posts
  • Glossary of Terms (A to Z)
  • Home Page
  • About
    • Join the Support Group
    • Recommendations
    • My Diagnosis and Treatment
      • My Neuroendocrine Cancer Surgery – Small Intestine NET, a patient experience (part 1)
      • My Neuroendocrine Cancer Surgery – a patient experience (part 2)
      • My liver rescetion
      • My lymphadenectomy
    • Ronny’s Video Presentations
    • Health Union Patient Leader
    • Disclaimer
    • Award Winning Blog
  • A spotlight on NENs
    • A spotlight on NENs – Types
      • A spotlight on Small Intestine Neuroendocrine Tumours
      • A spotlight on Appendiceal Neuroendocrine Neoplasms
      • A spotlight on duodenal Neuroendocrine Neoplasms (dNENs)
      • A spotlight on Rectal Neuroendocrine Neoplasms
      • A Spotlight on Lung Neuroendocrine Neoplasms
      • Neuroendocrine Tumours: a spotlight on Pheochromocytoma and Paraganglioma
      • A spotlight on Grade 3 (High grade) Neuroendocrine Neoplasms
    • A spotlight on NENs – Syndromes
      • A Spotlight on Neuroendocrine Cancer Syndromes – Carcinoid Syndrome
    • A Spotlight on NENs – Testing
      • Tumour markers and Hormone Levels
      • A spotlight on Chromogranin A
      • A spotlight on 5-HIAA
      • The NETest® – a Chromogranin A replacement and more?
  • Epidemiology
    • Neuroendocrine tumors are uncommon but definitely not rare
    • Neuroendocrine Neoplasms – not as rare as you think
    • The Invisible NET Patient Population 
    • Genetics
      • Neuroendocrine Neoplasms (NEN) – genetic related syndromes
      • A spotlight on Multiple Endocrine Neoplasia (MEN)
  • NET Guidelines
  • Diagnosis and Surveillance
    • Neuroendocrine Neoplasms – Classification, Grade and Stage
    • A spotlight on Gastric Neuroendocrine Neoplasms
    • Where to find a NET Specialist worldwide
    • 10 questions to ask your doctor
    • Diagnosing the Undiagnosed
    • A needle in a haystack?
    • Marker Tests
    • Syndromes and Symptoms
      • I bet my flush beats yours?
      • Neuroendocrine Cancer – the diarrhea jigsaw
      • The Syndromes of Neuroendocrine Cancer – Early Signs of a Late Diagnosis
      • Hormones
      • Neuroendocrine Cancer: Clinical Esoterica
      • Gallium 68 PET Scans – Into the Unknown
      • Serotonin – the NET effect
      • Cancer-related fatigue (CRF) – Neuroendocrine Cancer
      • Imaging
        • Neuroendocrine Cancer – If you can see it, you can detect it!
        • Ga68 PET Scan – a game changer?
        • Neuroendocrine Tumours – now you see them, now you don’t!
        • Detectnet™ (64Cu-DOTATATE) – an expansion of the Somatostatin Receptor PET Imaging for Neuroendocrine Cancer
        • Understanding your Somatostatin Receptor (SSTR) PET/CT Scan Results
  • Treatments
    • Treatment – a summary for patients
    • Surgery
      • Surgery for Neuroendocrine Neoplasms – to cut or not to cut?
      • Surgery for NETs – Chop Chop
      • Surgery is risky but so is driving a car
      • Small intestine, large surgery
      • Pancreatic Neuroendocrine Tumours – surgical decisions
      • Neuroendocrine Cancer – my liver surgery
    • Liver Embolization (bland, chemo, radio)
    • Somatostatin Receptors
    • PRRT
      • Peptide Receptor Radionuclide Therapy (PRRT)
      • Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future
    • Somatostatin Analogues
      • Somatostatin Analogues for Neuroendocrine Cancer: Lanreotide and Octreotide
      • Lanreotide – it’s calling the shots!
      • At home with Lanreotide (….and Octreotide)
      • Somatostatin Analogues and delivery methods in the pipeline
    • Everolimus (Afinitor)
    • Sunitinib (Sutent)
    • Chemotherapy
    • Telotristat Ethyl (XERMELO®)
  • Diet and Nutrition
    • Q. The best diet for Neuroendocrine Cancer? A. The one that works for you.
    • Article 1 – Vitamin and Mineral Challenges
    • Article 2 – Gastrointestinal Malabsorption
    • Article 3 – Gut Health
    • Article 4 – Food for Thought?
    • Article 5 – Pancreatic Enzyme Replacement Therapy (PERT)
    • Article 6 – featuring the 2020 video series by Tara Whyand RD
    • The trouble with the NET (Part 5) – Cancer Diet Myths
    • Lactose intolerance – the NET Effect
    • Fructose intolerance – the NET Effect
    • Low FODMAPs – The NET Effect
    • Low and High Residue Foods
  • Clinical Trials and Research
  • Awareness Posts
    • The Trouble with the NET Series
    • The NET Effect Series
    • All Awareness Posts
  • Glossary of Terms (A to Z)

Tag: Octreo-ratiopharm®

Ratiopharm. Ratiopharm is a German pharmaceutical company that is Europe’s leading generics brand (parent company is TEVA above).  It has a long acting octreotide branded as “Octreo-ratiopharm®“.  Appears to be in use in various EU countries including Germany and Finland according to patient feedback. Read more here.

  • Home
  • Octreo-ratiopharm®
Generic Somatostatin Analogues for Neuroendocrine Cancer
TreatmentBynfezia Pen, Generic drugs, Lanreotide, Octreo-ratiopharm®, Octreotide, Olatuton®, Sandostatin, Somatostatin analogues, Somatostatin receptors (SSTR), Somatuline Autogel (US: depot)

Generic Somatostatin Analogues for Neuroendocrine Cancer

By Ronny Allan Apr 22, 2021 10 Comments

Buy me a cup of tea?

Buy me a cup of tea or two? Change the number below to increment. i.e insert 2 = £8, 3 = £12, etc

Overheads to run this site, e.g. software packages, domain registration fees, software tools, misc items. Donate £4 or more so I have the fuel to keep on providing great content!

£4.00

  • Facebook
  • WhatsApp
  • Twitter
  • Facebook
  • Bluesky
  • Twitter
  • Instagram
  • Pinterest

Translate to any language

Find a Trial
  • Next Generation Total-Body PET/CT: Challenges and Opportunities
  • Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
  • Ronny Allan – a review of my blog activity December 2025
  • A review of 2025 on RonnyAllan.NET
  • 15 years of Christmas!
  • A spotlight on NENs
  • A spotlight on NENs – Syndromes
  • A Spotlight on NENs – Testing Series
  • A spotlight on NENs – Types
  • Awareness
  • Clinical Trials and Research
  • Diet and Nutrition
  • Fundraising
  • General
  • Humour
  • Inspiration
  • Latest ENETS Guidelines
  • Living with Neuroendocrine Cancer
  • Newsletters
  • Patient Advocacy
  • Ronny Allan's "The Trouble with the NET Series"
  • Sometimes you gotta climb that hill!
  • Spotlight on NENs – Types Series
  • Survivorship
  • The NET Effect Series
  • Travel with Ronny
  • Treatment
Category Cloud
A spotlight on NENs A spotlight on NENs - Syndromes A Spotlight on NENs - Testing Series A spotlight on NENs - Types Awareness Clinical Trials and Research Diet and Nutrition Fundraising General Humour Inspiration Latest ENETS Guidelines Living with Neuroendocrine Cancer Newsletters Patient Advocacy Ronny Allan's "The Trouble with the NET Series" Sometimes you gotta climb that hill! Spotlight on NENs - Types Series Survivorship The NET Effect Series Travel with Ronny Treatment
      Our website use cookies to improve and personalize your experience and to display advertisements(if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.
      Ok, I Agree
       

      Loading Comments...